title: Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
abstract: Chemotherapy-induced nausea and vomiting (CINV), both acute and delayed, has a dramatic effect on the well-being and quality of life of patients with cancer. Improved understanding of the mechanisms involved in CINV has led to the development of agents targeting the 5-HT3 receptor as well as the NK-1 receptor. Antiemetic prophylaxis given to patients receiving highly emetogenic chemotherapy combines agents blocking the 5-HT3 and NK-1 receptors along with corticosteroids given regularly and repeatedly. Rolapitant is a long-acting NK-1 receptor antagonist with proven efficacy in controlling CINV as part of the prophylaxis regimen. This review will detail the clinical efficacy and safety of rolapitant in the treatment of patients with cancer receiving highly or moderately emetogenic chemotherapy.
authors: Palliative Care, Ottawa Hospital Cancer Centre, Ottawa, Canada.|Palliative Rehabilitation Program, Élisabeth Bruyère Hospital, Ottawa, Canada.
authors: Martin R
authors: MR
authors: Chasen
authors: The Medical Oncology Centre of Rosebank, Saxonwold, Johannesburg, South Africa.
authors: Bernardo L
authors: BL
authors: Rapoport
mesh_terms: D000932:Antiemetics / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004347:Drug Interactions; D006801:Humans; D009325:Nausea / Q000188:drug therapy* / Q000209:etiology*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D064729:Neurokinin-1 Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D011788:Quality of Life; D018040:Receptors, Neurokinin-1 / Q000378:metabolism; D013141:Spiro Compounds / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014839:Vomiting / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D013141:Spiro Compounds; C578834:rolapitant
keywords: NK-1 receptor antagonist; antiemetic; aprepitant; chemotherapy-induced nausea and vomiting; delayed chemotherapy-induced nausea and vomiting; fosaprepitant; netupitant; palonosetron; rolapitant